Assessing the Potential of AstraZeneca's (AZN) Durvalumab + TapImmune's (TPIV) TPIV 200 in Platinum-Resistant Ovarian Cancer Ahead of Phase II Initiation This QuarterTicker(s): AZN, MRK, BMY, TPIV, RHHBY
An expert with significant experience treating patients with platinum-resistant ovarian cancer, who is familiar with the data behind durvalumab and TPIV 200. He or she will have knowledge of the current drugs in the space, and the regulatory process for similar drugs.
Can you describe your experience treating patients with platinum resistant ovarian cancer? What drugs are currently used to treat patients? What other ways are there of treating patients?Added By: pjloria
Can you discuss the safety, efficacy, and cost of current treatment options?Added By: pjloria
Can you discuss the previous data on durvalumab and TPIV 200, and what it suggests about the safety and efficacy of the combination?Added By: pjloria
Can you discuss the design of the Phase II study that will start this quarter, and important things to look for and focus on in the data?Added By: pjloria
Given the current information, how do you view the chances of approval for this combination therapy?Added By: pjloria
Assuming it gets approved, how will AstraZeneca and TapImmune's combination therapy compete with already approved PD1/PD-L1 products? Specifically Merck, Bristol-Myers Squibb's products? How does the combination compare to Roche's atezolizumab, which is expected to receive two FDA approvals this fall? If the drug is the fourth to market, does it stand any chance of succeeding?Added By: pjloria
Assuming atezolizumab and the combination of durvalumab/TPIV 200 both get approved, which of the previously mention PD1/PD-L1 products do you expect to dominate the market? What percentage of patients do you expect to use each drug?Added By: pjloria
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.